A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease

Clinical Neuropharmacology

Volumn 19, Issue 4, 1996, Pages 283-296

  Ruottinen, H M ^a   Rinne, U K ^a  

^a UNIVERSITY OF TURKU   (Finland)

Author keywords

Catechol O methyltransferase inhibitor; Entacapone; Levodopa; Levodopa related fluctuations; Parkinson's disease

Indexed keywords

3 O METHYLDOPA; 3,4 DIHYDROXYPHENYLACETIC ACID; BENSERAZIDE; CARBIDOPA; CATECHOL METHYLTRANSFERASE; DOPA DECARBOXYLASE INHIBITOR; ENTACAPONE; HOMOVANILLIC ACID; LEVODOPA;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DYSKINESIA; ENZYME ACTIVITY; ERYTHROCYTE; FAINTNESS; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; HUMAN CELL; MALE; MOTOR PERFORMANCE; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029895288     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199619040-00001     Document Type: Article

References (30)

1. Rinne UK. Treatment of Parkinson's disease: problems with progressing disease. J Neural Transm 1981;51:161-74.
2. Shoulson I, Glaubiger GA, Chase TN. On-off response. Neurology 1975;25:1144-8.
3. Sweet RD, McDowell FH. Plasma DOPA concentrations and the "on-off" effect after chronic treatment of Parkinson's disease. Neurology 1974;24:953-6.
4. Borgulya J, Bruderer H, Bernauer K, Zürcher G, Da Prada M. Catechol-O-methyl transferase-inhibiting pyrocatechol derivatives: synthesis and structure-activity studies. Helv Chim Acta 1989;72:952-68.
5. Bäckström R, Honkanen E, Pippuri A, et al. Synthesis of some novel potent and selective catechol O-methyltransferase inhibitors. J Med Chem 1989;32:841-6.
6. Männistö PT, Tuomainen P, Tuominen RK. Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat. Br J Pharmacol 1992;105:569-74.
7. Nissinen E, Linden I-B, Schultz E, Pohto P. Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor Entacapone. Naunyn Schmiedebergs Arch Pharmacol 1992;346:262-6.
8. Kaakkola S, Teräväinen H, Ahtila S, Rita H, Gordin A. Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology 1994;44:77-80.
9. Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994;44:913-9.
10. Myllylä VV, Sotaniemi KA, Illi A, Suominen K, Keränen T. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. Eur J Clin Pharmacol 1993;45:419-23.
11. Keränen T, Gordin A, Karlsson M, et al. Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. Eur J Clin Pharmacol 1994;46:151-7.
12. Ahtila S, Kaakkola S, Gordin A, et al. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopacarbidopa in volunteers. Clin Neuropharmacol 1995;18:46-57.
13. Merello M, Lees AJ, Webster R, Bovingdon M, Gordin A. Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57:186-9.
14. Ruottinen H, Rinne UK. Effect of one month's treatment with peripherally-acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. Clin Neuropharmacol 1996;19:222-33.
15. 18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease. Neurology 1994;44:1292-7.
16. 18F]fluorodopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson's disease. J Neural Transm [P-D Sect] 1995;10:91-106.
17. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-42.
18. Farm S, Elton RL, members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent developments in Parkinson's disease, vol II. Florham Park: Macmillan Healthcare Information, 1987:153-63.
19. Esteguy M, Bonnet AM, Kefalos J, Lhermitte F, Agid Y. Le test à la L-dopa dans la maladie de Parkinson. Rev Neurol 1985;141:413-5.
20. Schultz E, Nissinen E, Kaakkola S. Determination of catechol-O-methyltransferase activity in erythrocytes by high performance liquid chromatography with electrochemical detection. Biomed Chromatogr 1989;3:64-7.
21. Wikberg T. Simultaneous determination of levodopa, its main metabolites and carbidopa in plasma by liquid chromatography. J Pharm Biomed Anal 1991;9:167-76.
22. Karlsson M, Wikberg T. Liquid chromatographic determination of a new catechol-O-methyltransferase inhibitor, entacapone, and its Z-isomer in human plasma and urine. J Pharm Biomed Anal 1992;10:593-600.
23. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1982.
24. Jones B, Kenward M. Design and analysis of cross-over trials. London: Chapman and Hall, 1989.
25. Keränen T, Gordin A, Harjola V-P, et al. The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol 1993;16:145-56.
26. Sundberg S, Scheinin M, Illi A, Akkila J, Gordin A, Keränen T. The effects of the COMT inhibitor entacapone on haemodynamics and peripheral catecholamine metabolism during exercise. Br J Clin Pharmacol 1993;36:451-6.
27. Illi A, Sundberg S, Koulu M, Scheinin M, Heinävaara S, Gordin A. COMT inhibition by high-dose entacapone does not affect hemodynamics but changes catecholamine metabolism in healthy volunteers at rest and during exercise. Int J Clin Pharmacol Ther 1994;32:582-8.
28. Roberts JW, Cora-Locatelli G, Bravi D, Amantea MA, Mouradian MM, Chase TN. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology 1994;44:2685-8.
29. Limousin P, Pollak P, Gervason-Tournier C-L, Hommel M, Perret JE. Ro 40-7592, a COMT inhibitor, plus levodopa in Parkinson's disease. Lancet 1993;341:1605.
30. Davis TL, Roznoski M, Burns RS. Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline. Mov Disord 1995;10:349-51.